What is the equivalent dose of Coreg (carvedilol) when converting from Lopressor (metoprolol tartrate)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 8, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Conversion from Lopressor (Metoprolol Tartrate) to Coreg (Carvedilol)

When converting from Lopressor (metoprolol tartrate) to Coreg (carvedilol), the equivalent dose ratio is approximately 4:1, meaning 100 mg of metoprolol tartrate is equivalent to approximately 25 mg of carvedilol.

Conversion Guidelines

The 2022 AHA/ACC/HFSA Heart Failure Guidelines provide the following target doses for these beta-blockers 1:

Beta-Blocker Initial Daily Dose Target Dose Mean Dose in Clinical Trials
Metoprolol tartrate 25-100 mg BID 100 mg BID N/A
Metoprolol succinate 12.5-25 mg once daily 200 mg once daily 159 mg total daily
Carvedilol 3.125 mg twice daily 25-50 mg twice daily 37 mg total daily
Carvedilol CR 10 mg once daily 80 mg once daily N/A

Conversion Algorithm

  1. Calculate total daily metoprolol tartrate dose
  2. Divide by 4 to get total daily carvedilol dose
  3. Divide carvedilol dose by 2 for twice-daily dosing

Examples:

  • Metoprolol tartrate 50 mg BID (100 mg/day) → Carvedilol 12.5 mg BID (25 mg/day)
  • Metoprolol tartrate 100 mg BID (200 mg/day) → Carvedilol 25 mg BID (50 mg/day)

Important Clinical Considerations

Pharmacological Differences

  • Metoprolol is a selective β1-receptor blocker at lower doses but becomes less selective at higher doses 2
  • Carvedilol is a non-selective β1, β2, and α1-receptor blocker at all clinically relevant doses 2
  • Carvedilol has additional vasodilatory and antioxidant properties not present in metoprolol

Clinical Outcomes

  • The COMET trial demonstrated that carvedilol extended survival compared to metoprolol tartrate in heart failure patients (34% vs 40% all-cause mortality) 3
  • Carvedilol has more favorable metabolic effects in patients with diabetes and hypertension, with less impact on glycemic control compared to metoprolol 4

Practical Considerations

  • Start with a low dose of carvedilol (3.125 mg BID) when switching from metoprolol
  • Titrate gradually every 1-2 weeks based on blood pressure, heart rate, and symptoms 1
  • Monitor for orthostatic hypotension due to carvedilol's alpha-blocking effects
  • Consider patient's comorbidities (diabetes, COPD, etc.) when selecting beta-blocker

Titration Schedule

  1. Start with carvedilol 3.125 mg BID regardless of previous metoprolol dose
  2. If tolerated after 1-2 weeks, increase to 6.25 mg BID
  3. Continue doubling the dose every 1-2 weeks as tolerated
  4. Target dose is 25 mg BID for most patients (50 mg BID for patients >85 kg)

Cautions and Contraindications

Both medications are contraindicated in:

  • Severe bradycardia
  • High-grade AV block without pacemaker
  • Cardiogenic shock
  • Decompensated heart failure 1

Extended-Release Considerations

If switching from metoprolol tartrate to carvedilol CR (controlled-release):

  • Carvedilol CR allows once-daily dosing with equivalent efficacy to twice-daily immediate-release formulation 5
  • Use a 2:1 conversion ratio from total daily carvedilol IR dose to CR dose

Remember that the goal of beta-blocker therapy is to achieve the target doses shown to be efficacious in clinical trials, as this has been demonstrated to reduce cardiovascular mortality and heart failure hospitalizations 1.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.